Home
Valuation

Work Area: Valuation

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

IP finance, monetisation and much more take centre stage on Day One of IPBC Asia 2022

A broad range of subjects and talking points - including a plenary address from JPO Commissioner Koichi Hamano - kept the 400+ delegates engaged as the event got underway in Tokyo

Latest content

Investor interest in IP is about more than big money verdicts, claims Ocean Tomo transactions chief

Ten-figure awards in the patent space have caught capital’s attention, says Ocean Tomo's Ryan Zurek, but so has the IP market’s resilience in the face of economic turbulence

04 August 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020

20 July 2021

Singapore banking on regional IP rise and dispute resolution to cement its hub status

An update to the country’s strategy recognises that facilitating ASEAN's patenting development is key

19 July 2021

IAM insight panel analysis Q2 2021

Featured in Community Insight

Second quarter panels report finds a marked increase in negative views about the administration, but fewer covid concerns and signs of higher royalty and sales prices

01 July 2021

University and Big Pharma JV’s $145 million take-off is a big boost for tech transfer dealmaking

Apollo Therapeutics is an innovative biotech formed by three UK universities and three major companies, with a promising model for creating and monetising life sciences IP

29 June 2021

Via Licensing looks to extend its hold on audio space with next-gen patent pool

Company president Joe Siino tells IAM the pool operator has secured virtually all the key innovators behind MPEG-H to roll out a unified licensing solution

23 June 2021

In the mobile licensing world, US patent holdings do not have the power they did

Globalisation in the 5G era has reduced the clout of portfolios centred on the country, but decisions taken by the government, the courts and in boardrooms have hastened the process

17 June 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators

15 June 2021

Xiaomi royalty figures show importance of IP strategy as it grows international footprint

In a banner quarter, company gets off US government blacklist, grows profits, and pays a hefty royalty sum

01 June 2021

How to calculate ROI for patent portfolios and boost corporate value

The Long Read: These days, both the tools and data are available to develop models for creating significant value from corporate IP assets. All too often, though, what is still missing is the will to use them. Jeremiah Chan and Jonathan Liu of Facebook and Cipher’s Nigel Swycher and Steve Harris argue that a change of mindset among portfolio managers could reap significant rewards

19 May 2021

Unlock unlimited access to all IAM content